Vect-Horus signs scientific collaboration with Servier

French biotech firm Vect-Horus has signed a scientific collaboration agreement with France’s largest independent pharma company Servier. The companies did not disclose the financial terms of this agreement.

This collaboration is part of Vect-Horus’ framework strategy, which is to use its proprietary technology to enter into R&D agreements with biopharmaceutical companies to generate patentable new chemical entities (NCEs), based on the vectorization of their drug candidates.

This collaboration agreement with Servier reflects the growing interest in the drug delivery platform developed by Vect-Horus, whose co-founder and chief executive Alexandre Tokay said: “This research program, based on receptor targeting to facilitates delivery of therapeutic agents to the brain, is a true recognition of our scientific strategy.